Calidi Biotherapeutics (NYSE:CLDI) Releases Earnings Results, Beats Expectations By $0.20 EPS

Calidi Biotherapeutics (NYSE:CLDI) announced its quarterly earnings results on Tuesday. The company reported ($0.65) EPS for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.20, Zacks reports.

Calidi Biotherapeutics Price Performance

NYSE CLDI traded up $1.00 on Wednesday, hitting $3.11. The stock had a trading volume of 17,468,279 shares, compared to its average volume of 350,203. Calidi Biotherapeutics has a 52-week low of $0.73 and a 52-week high of $26.30. The business has a 50-day moving average of $1.19.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.